The early days of prosthetic valve development provided much information that is still of value today.
What can we learn from the good, the bad and the ugly experiences of the pioneers of valve innovation? P e e r r e v ie w e d a r tic l e
We would like to give an overview of the history and evolution of heart valves, focusing not only on the technical features of each prosthesis, but also on the trends and mechanisms that influenced this continuous development. We have divided the paper in sections that each describe the evolution of a subtype of heart valve, from mechanical and biological surgical prostheses to the transcatheter valves, and explain the reasons that determined the emergence of the "nextstep valve". With this purpose, we are not going to mention all the devices, but take example of the major ones to understand the trend of evolution. Hufnagel prosthesis with a nylon one coated with a silicone rubber. Initial preclinical studies with mechanical valves showed the high level of anticoagulation needed to avoid valve occlusion and an elevated risk of thromboembolic events was also described.
First steps in heart valve surgery
All these aspects were already clear in the first decades of heart valve surgery and they have steadily guided the evolution of heart valve prostheses. These "old concepts" will be the "key words" adopted in this review, to explain the prostheses' evolution.
Mechanical heart valves: past, present and future
The poor haemodynamic performances of the "ball- After more than 50 years of evolution, mechanical valve replacement represents an optimal treatment for patients with heart valve disease. Mortality decreased progressively and no differences in term of prognosis have been described when comparing mechanical with biological valves [16] [17] . Figure 1 shows the evolution of mechanical heart valve prostheses.
But what can we expect in the current era from this old tool? Could innovation in valvular heart therapies alter the role of mechanical valves? Could mechanical valves benefit from new anticoagulation strategies?
Studies in animals showed that dabigatran was effective in preventing valve thrombosis and was associated with reduced mortality after mitral valve surgery.
These encouraging data have not yet translated into human practice [18] . New materials could be less thrombogenic and patient selection could be redefined accordingly, but there is not yet sufficient evidence to change the standard anticoagulation management.
As a matter of fact, today most patients prefer to receive a tissue valve, to avoid anticoagulation, and the age threshold is continually reduced in guidelines, ranging between 60 and 65 years.
Reducing anticoagulation-related events: the advent of biological valves
The evolution of biological tissue valves is a mix of biochemistry, mechanical engineering and biology. A tissue valve provides some clear advantages in terms of biocompatibility, with concerns related to its durability. The development of percutaneous heart valves brought together the evolution of bio-valves, stents and delivery catheter design. In order to permit endovascular releasing, the prosthesis should be crimped, with a decrease in dimensions of more than three folds without any damage to the leaflet. Two types of stents were developed: the stainless steel baloon-expandable stent and the self-expanding nitinol ones ( fig. 4 ).
Since the beginning of this technology several issues have been identified as potential limiting factors: paravalvular leakage, a high rate of vascular complications, risk of neurological events and complete atrioventricular block.
The Cribier-Edwards (previously PVT) balloon-expandable valve (Edwards Lifesciences) was the first transcatheter aortic prosthesis (2002) . It consisted initially of equine pericardium and a stainless-steel frame. In order to improve sealing, a polyethylene terephthalate fabric skirt was introduced; this modification represented the first Edwards SAPIEN model (2006) [34] .
Owing to the high profile of the delivery system, several patients were treated via a transapical approach.
The SAPIEN XT (2009) Innovation profoundly changed the clinical use of TAVI. In contrast to the early stages, when its use was limited to high risk and inoperable patients, intermediate-risk patients are currently treated since recent data showed that TAVI is a non-inferior, and sometime superior, alternative to surgery in the short term.
The design of TAVI valves gives them optimal haemo- dynamic results [35] , which might support the clinical superiority, particularly in patients at risk of PPM.
The transcatheter approach is also used in the treat- 
Beyond the present: tissue-engineered heart valves
All the devices described exhibit a lack in remodelling and growth capability. This concept has led to the development of innovative valve substitutes called regenerative valves or tissue-engineered valves (TEHVs).
This novel approach is based on various tissue engineering technologies that provide an alternative crimp able valve replacement device thought to be a definitive solution, also for younger and paediatric patients [39] .
A TEHV would be a living organ, capable of responding and growing like the native valve. The immune response plays a special role in regulating remodelling after implantation. This technology aims to become the most advanced means to improve valve durability [40] .
Experience with TEHVs is still preclinical and, even if transcatheter implantation is successfully performed in animal models, the way the device could interact with a calcified annulus must be clarified, before it can be translated into clinical practice [39, 40] . 
What can we expect from new-era prostheses and new-era physicians?
The 
